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Abstract 
Background & Aims: To estimate accuracy of FibroScan vibration-controlled transient 
elastography (VCTE) controlled attenuation parameter (CAP) and liver stiffness measurements 
(LSM) to detect steatosis and fibrosis in patients with suspected NAFLD. 
Methods: Between 03/2014 and 01/2017, 450 consecutive adult patients undergoing clinically 
indicated liver biopsy (LB) for NAFLD were prospectively recruited in 7 UK centres. 
FibroScan examinations with M or XL probe were completed within the 2 weeks of LB.  LB 
were scored blindly by two expert pathologists according to NASH clinical research network 
criteria. Diagnostic accuracy was estimated using the area under the receiver operating 
characteristic curve (AUROC) across categories of steatosis and fibrosis. The influence of 
disease prevalence on positive and negative predictive values (PPV/NPV) was assessed. For 
LSM, the influence of histological parameters and probe type was appraised using 
multivariable analysis. 
Results: 404/415 patients had a valid FibroScan examination (applicability 97%). CAP 
identified patients with steatosis with an AUC of 0.87 (95% CI:0.82-0.92) for S≥S1, 0.77 (0.71-
0.82) for S≥S2 and 0.70 (0.64-0.75) for S=S3. LSM identified patients with fibrosis with an 
AUC of 0.77 (0.72-0.82) for F≥F2, 0.80 (0.75-0.84) for F≥F3 and 0.89 (0.84-0.93) for F=F4. 
Applying the optimal cut-offs found in this cohort to lower fibrosis prevalence populations 
markedly increased NPV and reduced PPV. Multivariable analysis demonstrated the only 
parameter significantly influencing LSM was fibrosis stage (P < 10-16), with no association 
seen for steatosis or probe type. 
Conclusion: CAP and LSM by FibroScan are reliable biomarkers to non-invasively assess 
liver steatosis and fibrosis respectively in NAFLD. Probe type and steatosis do not influence 
LSM. 
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Background & Aims:  
Non-alcoholic fatty liver disease is an increasingly common cause of chronic liver disease, and 
is expected to soon become the commonest indication for liver transplantation1, 2. Estimates of 
its prevalence vary from 20-40% in the general population, although only 1-3% have evidence 
of significant inflammation and fibrosis3. The presence of liver fibrosis in particular is an 
important predictor of clinical events, both in terms of overall mortality and also liver-related 
morbidities and mortality4, 5. The challenge therefore remains how to identify those individuals 
with NAFLD that have more significant pathology in a manner which is non-invasive and 
affordable by healthcare systems. 
 
Vibration-controlled transient elastography (VTCE) is one such approach which is in 
widespread clinical usage and for which there is an increasing understanding of clinically 
relevant cut-off values. By the use of a pulse-echo ultrasonic acquisition, vibration-controlled 
transient elastography (VCTE) can quantify the speed of a mechanically induced shear wave 
in liver tissue and hence generate an estimate of the degree of liver fibrosis with a liver stiffness 
measurement (LSM)6, 7. More recently this has been supplemented by the ability to quantify 
hepatic steatosis by measuring ultrasonic attenuation of the echo wave, termed the controlled 
attenuation parameter (CAP)8, 9, which has been compared to liver biopsy in prospective studies 
with the M probe10-12.  
 
Previous studies have demonstrated the limitations of the M probe in patients with an increased 
skin to liver capsular distance as can occur commonly in NAFLD and overweight/obese 
patients13, 14; there is a much higher failure rate which led to the development of the XL probe. 
However, much of the published literature with the XL probe and CAP consists of either 
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retrospective15 or small/medium prospective cohort studies16-19, with the exception of the recent 
NASH CRN studies20, 21. However, none have been the subject of large prospective powered 
diagnostic studies adhering to standards for reporting of diagnostic accuracy studies (STARD) 
guidelines22.  
 
Importantly, there are still uncertainties about the impact of other histological features on LSM 
readings with reports suggesting that steatosis may be a contributor23, 24, although these studies 
were limited in that only the M probe was used. Similarly, whilst the advent of the XL probe 
has markedly reduced the failure rate in overweight/obese individuals25, there are reports 
suggesting that cut-off ranges differ according to probe choice26. 
 
We designed a large prospective diagnostic study across 7 centres in the United Kingdom to 
evaluate the diagnostic accuracy of CAP measured either with the M or XL probe (depending 
on the FibroScan device automatic probe recommendation tool) in patients being investigated 
for potential NAFLD compared to a reference standard of histological evaluation of steatosis. 
The secondary objectives were to evaluate the diagnostic accuracy of LSM (with either M or 
XL probe) compared to a reference standard based on histological evaluation of fibrosis, and 
study of impact of histological parameters and probe type on LSM reading. In addition we 
aimed to identify cutoffs for use in clinical practice with both CAP and LSM.  
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Methods 
Study participant and design 
The study was a cross-sectional prospective multi-centre study, with the primary and secondary 
outcomes being to assess the diagnostic accuracy of CAP and LSM against liver histology 
which is the gold standard to evaluate the liver steatosis and fibrosis. NAFLD was suspected 
on the basis of the presence of abnormal liver enzymes in the presence of an ultrasound scan 
showing and echobright liver was the principle reason, usually in the presence of metabolic 
syndrome components. The STARD guidelines were followed to report the methods and results 
of this study22 (see Supplementary Table 1 for further details). Consecutive patients were 
prospectively recruited between March 2014 and January 2017 in 7 liver centres across the 
United Kingdom (University Hospitals Birmingham NHS Foundation Trust, Birmingham; 
Addenbrooke’s Hospital, Cambridge; Royal Free Hospital, London; Freeman Hospital, 
Newcastle upon Tyne; University Hospitals Plymouth NHS Trust, Plymouth; Queen’s Medical 
Centre, Nottingham and John Radcliffe Hospital, Oxford). 
 
The study (NCT01985009) was approved by the North Wales Research Ethics Committee 
(13/WA/0385) and by the Local Research Ethics Committee at each centre. All patients gave 
written informed consent to participate in the study. The study was conducted in accordance 
with the declaration of Helsinki and in agreement with the International Conference on 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP). All authors had access to 
the study data and reviewed and approved the final manuscript. 
 
Main analyses: The primary outcome of the protocol was to evaluate the diagnostic accuracy 
of CAP measured either with the M or XL probe (depending on the FibroScan device automatic 
probe recommendation tool) against histological evaluation of steatosis. A secondary outcome 
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of the protocol was to evaluate the diagnostic accuracy of liver stiffness measured either with 
M or XL probe (depending on the FibroScan device automatic probe recommendation tool) 
against histological evaluation of fibrosis. 
  
Inclusion and exclusion criteria 
Inclusion criteria were as follows: patients were ≥18 years of age, able to give written informed 
consent and were scheduled, independently from this study, to have a liver biopsy (LB) for 
investigation of assumed NAFLD within 2 weeks of Fibroscan examination (before or after). 
Patients were also negative for HBsAg, anti-HCV, HCV-RNA and HBVDNA. Exclusion 
criteria were as follows: patients with ascites, pregnant women, patient with any active 
implantable medical device (such as pacemaker or defibrillator), patients who had undergone 
liver transplantation, patients with cardiac failure and/or significant valvular disease, patients 
with haemochromatosis, patients that refused to undergo liver biopsy or blood tests, patients 
with an alcohol consumption above recommended limits (>14 units/week for women and >21 
units/week for men; 1 unit = 8 g of ethanol), patients with a confirmed diagnosis of active 
malignancy, or other terminal disease, patient participating in another clinical trial within the 
preceding 30 days. 
 
Patient Characteristics 
The following characteristics were recorded for each patient: age, gender, BMI, presence of 
diabetes, hypertension, and hypercholesterolemia. For each patient, a 12 hour fasting blood 
collection was performed locally on the same day of the FibroScan procedure and was then 
shipped to a central laboratory for assessment of the following laboratory parameters: platelets 
count, international normalized ratio (INR), aspartate transaminase (AST), alanine 
transaminase (ALT), gamma-glutamyl-transferase (GGT), alkaline phosphatase, albumin, 
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bilirubin, fasting glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, triglyceride, ferritin, urea, creatinine, alpha-2-
macroglobulin (A2M), hyaluronic acid, C-reactive protein (CRP) and cytokeratin 18 neo-
epitope M30 (CK18-M30). 
 
Histopathologic evaluation 
Percutaneous LB was performed on all patients according to local standard procedure LB 
specimens were fixed in formalin, embedded in paraffin and stained with Hematoxylin and 
Eosin and Sirius Red for fibrosis evaluation. Slides were analysed independently by two 
experienced pathologists (PB and VP) who were blinded to each other’s reading and also to 
the patient’s clinical and Fibroscan data if available. In case of disagreement, they reviewed 
the slides together to reach consensus. 
 
Steatosis (from 0 to 3), ballooning (from 0 to 2), lobular inflammation (from 0 to 3), fibrosis 
(from 0 to 4) and NAFLD activity score (NAS) were scored using the NASH clinical research 
network (NASH CRN) scoring system 27. NASH was diagnosed using the “fatty liver: 
inhibition of progression” (FLIP) definition (presence of steatosis, hepatocyte ballooning and 
lobular inflammation with at least 1 point for each category). In addition, steatosis was semi-
quantitatively assessed in percentage and the activity score (Ballooning (0-2) plus lobular 
inflammation (0-2)) according to the Steatosis Activity Fibrosis (SAF) was also assessed 28. 
The presence of portal inflammation was also recorded. Biopsies were categorised by the 
pathologists as normal liver (no liver pathology), NAFL (steatosis but no NASH), NASH or 
other diagnosis when no NAFLD but other histological features suggestive of another 
diagnostic were observed (e.g. granulomatous hepatitis, biliary disease, autoimmune hepatitis). 
Interpretability for liver biopsy was based on the standard criteria of length, width and lack of 
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major fragmentation. These criteria were occasionally over-looked by the pathologist when the 
biopsy showed obvious histological criteria of NASH, septal fibrosis or cirrhosis even if the 
biopsy was small or fragmented. 
 
FibroScan liver stiffness measurement and controlled attenuation parameter 
FibroScan (Echosens, Paris, France) examination was performed in each centre by nurses or 
physicians trained and certified by the manufacturer and blinded to the patient’s histological 
evaluation. The FibroScan used in each center was a FibroScan 502 Touch model, equipped 
with both M and XL probes. An automatic probe selection tool was embedded in the device 
software which recommends the appropriate probe for each patient according to the real time 
assessment of the skin to liver capsule distance. The FibroScan examination procedure has 
been detailed previously6, 29. Briefly, all patients were asked to fast at least 3 hours prior to the 
examination, and then placed in the supine position with their right arm fully abducted. 
Measurements were performed by scanning the right liver lobe through an intercostal space.  
 
The FibroScan device simultaneously measures LSM and CAP using VCTE technology. CAP 
has been designed to measure liver ultrasonic attenuation (go and return path) at 3.5 MHz on 
both M and XL probes8, on signals acquired by the Fibroscan. The principle of CAP 
measurement has been described elsewhere8, 9, and CAP was computed only when the 
associated LSM was valid and using the same signals as the one used to measure liver stiffness. 
At the beginning of the study, CAP was not available on the XL probe, therefore, the raw 
ultrasonic radio-frequency signals were stored in the Fibroscan examination file to enable 
computation of CAP off-line. CAP computation was performed blinded to all patients’ clinical 
and histological data using the exact same configuration and algorithm to the one embedded in 
the commercial device for N=116 patients. When CAP was commercially available for the XL 
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probe, all software were updated and the CAP value was displayed on the device screen for 
both probes during the procedure. The final CAP and LSM results were expressed in dB/m and 
kPa respectively. Only examinations with at least 10 valid individual measurements were 
deemed valid. 
 
Statistical Analysis 
Sample size estimation: Since no study had been performed previously using the probe 
recommendation on the FibroScan device, the sample size was calculated for patient measured 
with the XL probe only. It was hypothesized that approximately 1/3 of the total patients would 
be measured with M probe. Given the expected performance of CAP to detect steatosis (S≥S1) 
with an AUROC≥0.809, 30, 31, a projected sample size of 212 patients was deemed necessary to 
estimate an AUROC of 0.80 with the XL probe with an (1-) confidence interval,  being set 
to 5%, at a 5% standard error level, for the XL probe only. The total number of patients 
measured using both probes was set to 312 patients and the final number of patients was set at 
450 assuming a 30% drop-out rate   
 
For descriptive statistics, continuous variables were expressed as medians [interquartile range 
(IQR)] and categorical variables as absolute figures with percentages. Confidence intervals 
were reported at the 95% level. Evidence for differences between CAP and LSM between 
steatosis grades and fibrosis stages was assessed using Kruskal-Wallis test followed by Dunn's 
tests with post hoc comparison. P values of < 0.05 were considered statistically significant. 
 
Overall diagnostic accuracy of CAP and LSM was estimated as the area under the ROC curve 
(AUROC) together with its 95% confidence interval (CI). Data are reported for thresholds of 
steatosis and fibrosis. Cut-off values for CAP and LSM were identified that (a) maximise the 
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Youden index, and also (b) at fixed values of sensitivity and specificity of 90%. For each cut-
off value, we reported sensitivity (Se), specificity (Sp), positive predictive value (PPV), 
negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio (LR-
) together with 95% confidence intervals. In additional analyses we investigated the 
performance of the tests in settings with different prevalence using Bayes equation to estimate 
post-test probabilities from the estimated likelihood ratios. For these computations we focused 
on fibrosis thresholds of F≥F2 and F=4 which are of particular importance as they correspond 
with stages which result in changes in patient management. We also identified cutoffs which 
minimized the consequences of test errors across different relative weightings of false positives 
and false negatives (see Supplementary Methods). 
 
Factors influencing LSM: To evaluate the impact of histological parameters that possibly 
influenced LSM, a multivariable linear regression model was constructed with fibrosis stage, 
steatosis grade, ballooning grade, lobular inflammation and portal inflammation as candidate 
covariates and LSM as the outcome variable. In addition, the probe type used (M or XL) was 
also entered as a candidate covariate to evaluate if it had an impact on LSM when adjusted on 
histological parameters. All first order interactions were entered into the model. LSM was Box-
Cox transformed to approximate a normal distribution. Final model selection was performed 
with a backward elimination procedure based on Bayesian information criteria (BIC). Multi-
collinearity of independent variables was checked using the variance inflation factor.  In 
addition to this multivariable analysis, LSM versus fibrosis stage stratified by probe type and 
by semi-quantitative steatosis percentage quartile was represented using a boxplot. Univariate 
analysis was performed using Kendall rank correlation coefficient between each histological 
parameter and LSM and was performed using the Mann-Whitney U test between the probe 
type and LSM. 
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The sensitivity analyses on CAP and LSM diagnostic accuracy and the analyses relative to the 
influence of disease prevalence on PPV and NPV, the cutoffs which minimized the 
consequences of test errors across different relative weightings of false positives and false 
negatives and factors influencing LSM were exploratory analyses which were not pre-
specified.  
 
For all analyses, only patients with histological results and median LSM or CAP values 
available with at least ten valid measurements were analyzed. In addition, no replacement of 
missing data has been performed. All analyses were performed using the software R, version 
3.3.032. 
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Results 
Patient Characteristics 
The study flow chart is represented in Figure 1. Table 1 details the clinical, serological, 
histological characteristics and Fibroscan data of 383 patients with a valid FibroScan reading 
and an interpretable liver biopsy.  
 
FibroScan applicability  
Of 415 patients evaluated using the FibroScan (Figure 1), 138 (33%) were with the M probe 
and 277 (67%) with the XL probe. FibroScan readings were valid (with at least 10 valid 
individual measurements as per the manufacturer's recommendations) in 404 patients leading 
to an applicability value of 97%. For the 11 patients for whom a valid FibroScan was not 
achieved; 2 were with the M probe and 9 with the XL probe. Of note 4 of these 11 patients had 
9 valid measurements (rather than the 10 required). Patients with less than 9 valid 
measurements (n=7) had a significantly higher BMI than others (46.5 [13.6] kg.m-2 versus 36.4 
[9.2] kg.m-2; P = 0.003). Within the 404 patients with valid FibroScan, patients assessed with 
the XL probe (N=268) had a significantly higher BMI than patients measured by the M probe 
(36.3 [7.8] kg.m-2 versus 29.3 [4.7] kg.m-2; P < 10-16). No adverse event has been reported 
related to the use of the FibroScan device. 
 
Liver biopsies 
A total of 412 patients underwent LB (see Figure 1: 433 eligible patients minus 16 patients 
who did not have LB, 4 patients who had LB cancelled by the investigator and 1 patient who 
withdrew consent before LB). The LB slides of 3 patients were lost during shipment and a 
further 15 LB were judged as non-interpretable by the pathologist leaving 394 (96%) as having 
an interpretable LB. A further ten patients had a LB that although interpretable by the 
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pathologist could not be staged according to the NASH CRN scoring system. A description of 
those LB is provided in Supplementary Table 2 (2 patients being NAFLD with associated 
lesions and 8 being not NAFLD but not normal liver). Of note, 33 patients (8% of the patients 
with interpretable LB) had a histological diagnosis other than NAFLD or normal liver. A 
description of those LB is provided in Supplementary Table 2. After LB, 3 adverse events were 
reported: 1 patient had a syncopal episode following LB and pain at LB site requiring oral 
analgesia, 1 patient had hemorrhage following LB requiring hospitalization and 1 patient was 
admitted with pain and fever.  
 
Assessment of steatosis using controlled attenuation parameter 
Of 415 patients, 380 patients had an interpretable liver biopsy and valid CAP values (Figure 
1). According to histological assessment, steatosis grade distribution was as follows: S0 = 47 
(12%), S1 = 89 (23%), S2 = 107 (28%), S3 = 137 (36%) and the boxplot of CAP versus 
steatosis grade is shown in Figure 2a. CAP was significantly different between S0, S1 and S2 
but not S2 and S3 (Kruskal-Wallis H = 97.70, P < 10-16; Dunn's post hoc tests, P = 0.19 between 
CAP in S2 and CAP in S3, P < 10-3 otherwise). Areas under the ROC curve (AUROC) as well 
as diagnostic performance of CAP cut-off values optimized using Youden’s index, a sensitivity 
of 90% or a specificity of 90% are detailed in Table 2 for S0 versus S1 and above, S0-S1 versus 
S2-S3 and S0-S2 versus S3. Accuracy was highest at the S≥S1 threshold, with an AUROC of 
0.87 (95% CI: 0.82-0.92) and sensitivity of 0.80 (0.75-0.84) and specificity of 0.83 (0.69-0.92) 
at a threshold of 302 dB/m selected by maximizing Youden’s Index. Accuracy dropped to an 
AUC of 0.77 (0.71-0.82) for the S≥S2 threshold, with the corresponding sensitivity of 0.70 
(0.63-0.75) and specificity of 0.76 (0.68-0.83) at the threshold of 331 dB/m maximizing 
Youden’s index and to an AUROC of 0.70 (0.64-0.75) for the S=S3 threshold with the 
corresponding sensitivity of 0.72 (0.63-0.79) and a specificity of  0.63 (0.56-0.69) at the 
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threshold of 337 dB/m maximizing Youden’s index. The ROC plots for S≥S1, S≥S2 and S=S3 
are given in Supplementary Figure 1. Performance of CAP to diagnose NASH was also 
assessed. Corresponding AUC was 0.71 (0.65-0.76). 
 
 
The use of quality criteria based on the IQR of CAP as proposed by Caussy et al 33 and Wong 
et al 34 which recommend excluding patients with IQR of CAP greater or equal to 30 dB/m or 
40 dB/m, respectively was tested in our cohort. A large proportion of patients (xx) had an IQR 
of CAP ≥30 or 40 dB/m (57% and 39%, respectively), and performance was no better in 
patients with an IQR of CAP <30 or <40 dB/m (Supplementary Table 36). Indeed for the 
diagnosis of higher stages of steatosis performance was even lower in patient with an IQR of 
CAP <30 or <40 dB/m. To determine the influence of serum ALT on CAP diagnostic 
performance patients were stratified by ALT values (≤ULN, between ULN and 2xULN and 
>2xULN), but this did not influence CAP AUROCs (Supplementary Table 47). Performance 
of CAP was compared to the hepatic steatosis index (HSI) 35 in a subset of patients (N=375, 
due to 5 missing biological data). CAP significantly outperformed HSI for each steatosis grade 
S≥S1, S≥S2 and S=S3 (Supplementary Table 58). 
 
 
Assessment of fibrosis using liver stiffness measurement 
Of the 384 patients with valid LSM and interpretable LB, only 373 had fibrosis interpretable 
according to the NASH CRN scoring system (Figure 1). Differences in characteristics between 
the 373 patients used for fibrosis staging analysis and the 10 patients with fibrosis not staged 
are given in Supplementary Table 63. 
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Fibrosis stage distribution was as follows: F0: 62 (17%), F1: 86 (23%), F2: 85 (23%), F3: 106 
(28%), F4: 34 (9%). LSM versus fibrosis stage is presented as a boxplot in Figure 2b. LSM 
was significantly different between all fibrosis stages with the exception of F0 and F1 (Kruskal-
Wallis H = 119.8, P < 10-16; Dunn's post hoc tests, P = 1 between LSM in F0 and LSM in F1, 
P < 0.05 otherwise). AUC as well as diagnostic performance of LSM cut-off values optimized 
using Youden index, a sensitivity of 90% or a specificity of 90% are detailed in Table 3 for F0-
F1 versus F2 and above, F0-F2 versus F3-F4 and F0-F3 versus F4. Accuracy was highest at 
the F=F4 threshold, with an AUC of 0.89 (95% CI: 0.84-0.93) and sensitivity of 0.85 (0.69-
0.95) and specificity of 0.79 (0.74-0.83) at a threshold of 13.6 kPa selected by maximizing 
Youden’s Index. Accuracy was lower at lower fibrosis thresholds dropping to an AUROC of 
0.80 (0.75-0.84) for F≥F3 with the corresponding sensitivity of 0.71 (0.62-0.78) and a 
specificity of 0.75 (0.69-0.80) at a threshold of 9.7 kPa maximizing the Youden’s index and to 
an AUROC of 0.77 (0.72-0.82) for the F≥F2 threshold, with the corresponding sensitivity of 
0.71 (0.64-0.77) and specificity of 0.70 (0.62-0.77) at the threshold of 8.2 kPa maximizing the 
Youden’s index. The ROC plots for F≥F2, F≥F3 and F=F4 are given in Supplementary Figure 
2. Performance of LSM to diagnose NASH was also assessed. Corresponding AUC was 0.68 
(0.62-0.74). 
 
The performance of the Boursier criteria36 as a quality control for Fibroscan were evaluated in 
this cohort (IQR/median<30% in patient with LSM≥7.1 kPa). Whilst 43 (12%) patients did not 
reach the Boursier criteria, analysis in this cohort did not find evidence that these criteria 
improved performance of Fibroscan (Supplementary Table 79) where we have assessed 
AUROC for patients reliable according to Boursier’s criteria only. The influence of ALT on 
LSM or CAP diagnostic performance was evaluated by stratifying patients on ALT values 
(≤ULN, between ULN and 2xULN and >2xULN). No significant influence of the effect of 
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ALT on the LSM AUROC for each fibrosis stage or on the CAP AUROC for each steatosis 
grade was observed (Supplementary Table 810). The performance of the Baveno VI cut-offs37, 
in relation to patients with compensated advanced chronic liver disease with advanced fibrosis 
(F≥F3) were tested in this cohort. The NPV associated with the ≤10 kPa cutoff was 0.80 and 
the PPV associated with the ≥15 kPa cutoff was 0.75. 
Performance of LSM was also compared to Fib438 and the NAFLD fibrosis score (NFS39). 
Diagnostic performance in terms of AUROC for each fibrosis stage (≥F2, F≥F3 and F=F4) are 
provided in Supplementary Table 911. LSM outperformed Fib4 and NFS for the diagnosis of 
cirrhosis and NFS for the diagnosis of F≥2. For the diagnosis of advanced fibrosis, performance 
of LSM was compared using the dual cut-offs (cut-off for Se≥0.90 = 7.1 kPa and cut-off for 
Sp≥0.90 = 14.1 kPa determined in the present cohort) against the dual cut-offs for Fib4 (1.30 
and 3.25)38 and NFS (-1.455 and 0.676)39. LSM had a higher Se for the confirmation of 
advanced fibrosis (F≥3) with a PPV = 0.74 (Supplementary Table 102). 
  
Further analysis was performed to identify cutoffs which minimized the consequences of test 
errors across different relative weightings of false positives and false negatives (see 
Supplementary Results and Supplementary Table 114). In these analyses the consequences of 
diagnostic error were explored in situations where the priority was to either avoid false positive 
diagnoses (for the diagnostic of F≥F2) or false negative diagnoses (for the diagnostic of F=F4). 
The analyses were performed under a range of scenarios with the cost of a false positive (FP) 
being set at 2 times, 5 times and 10 times worse than a false negative (FN) for the diagnostic 
of F≥F2. The effect on threshold is shown in Supplementary Table 114 along with the corollary 
analyses for the diagnostic of F=F4.   
 
Impact of fibrosis prevalence on predictive value of liver stiffness measurement 
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We set out to determine the impact of fibrosis prevalence on PPV and NPV values by utilising 
a range of different pre-test probabilities values (prevalence). The prevalence figures used 
represent values from this cohort (60, 38% and 9% for F≥F2, F≥F3 and F=4 respectively) and 
also values seen in cohorts of patients with type 2 diabetes mellitus, patients at risk of liver 
disease and the general population40-42. For a diagnosis of F≥F2, F≥F3 and F=F4 there was a 
marked reduction in the PPV as the prevalence of fibrosis was lowered (Table 4). Rounding 
the proposed cut-offs did not affect the PPV and NPV, irrespective of prevalence (see 
Supplementary Table 121). 
 
Influence of probe type and histological parameters on liver stiffness measurement 
We next investigated the influence of probe type and histological parameters on LSM values. 
In univariate analysis, no significant difference was found between LSM and the probe type (P 
= 0.55); all histological parameters were significantly correlated to LSM: fibrosis stage ( = 
0.43, P < 10-16), ballooning grade ( = 0.22, P < 10-7), lobular inflammation grade ( = 0.21, P 
< 10-6), portal inflammation grade ( = 0.17, P < 10-4) and steatosis grade ( = 0.11, P = 0.004). 
Then, a multivariable linear regression analysis was performed. Following a backward 
selection procedure based on BIC, the only covariate influencing LSM was fibrosis stage (β = 
0.18, 95% CI = (0.15-0.21), P < 10-16). When adjusted for fibrosis stage, there was no 
significant influence of probe type or steatosis grade on the LSM value. To further illustrate 
this, a boxplot of LSM versus fibrosis stage stratified by probe type is presented in Figure 3a 
and a boxplot of LSM stratified by semi-quantitative steatosis percentage quartile is presented 
in Figure 3b.  
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Conclusions 
This prospective study examined the association of contemporaneous VTCE and liver 
histology in a cohort of patients undergoing liver biopsy for investigation for suspected 
NAFLD, and the results were reported according to the STARD guidelines. It demonstrates the 
high applicability rate of VTCE (97%) in a large UK NAFLD cohort with BMI up to 53.2 
kg/m² and provides optimised cut-off values for staging steatosis and fibrosis depending on 
prevalence and clinical context (Youden criteria, 90% sensitivity or 90% specificity). This 
study also provides novel approaches to threshold setting taking into account the prevalence of 
fibrosis in the population to be tested and also basing thresholds around clinical priorities such 
as minimising false positive diagnoses of F≥F2 or false negative diagnoses of F=4. Critically 
this study demonstrates that only fibrosis stage, and not probe type or any other histological 
parameters, influence LSM values.  
 
Whilst the cut-offs for steatosis grade increase progressively from S0 to S3 when set for high 
sensitivity or high specificity there is not much difference between S2 and S3 when using the 
Youden cut-off. The determination of steatosis by CAP is relevant for the confirmation of any 
degree of steatosis and also potentially as a serial measure in response to lifestyle or 
pharmacological/surgical intervention. The former is demonstrably feasible in this study 
whereas the latter will require examination in intervention studies. With regards to the 
association between LSM values and histological evaluation of liver fibrosis there is a clear 
demarcation between the different degrees of fibrosis for Youden cut-off as well as for those 
with high sensitivity or specificity. As expected the cut-off for liver cirrhosis is markedly higher 
at 20.9 kPa when the specificity is set at 90%.  
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The diagnostic performance of LSM and cutoffs for stages of fibrosis in this study are broadly 
in keeping with data from a US cohort20 (Supplementary Table 135) and those published in a 
UK guideline43. Whilst reasonably similar there are some differences in the UK cohort such as 
gender (45% female vs 68% female in US cohort) and presence of diabetes mellitus (50% vs 
44% in US cohort). For CAP however, diagnostic performance is higher in our cohort than in 
the US cohort (AUROC 0.87 (0.82-0.92) for the diagnostic of S≥1 in our cohort versus 0.76 
(0.64-0.89) in the US cohort. This difference may be accounted to the prevalence of patients 
with S≥S1 steatosis which is 88% in our cohort versus 95% in the US cohort. Another 
possibility is that the delay between FibroScan and LB was up to 12 months in NASH CRN 
study whereas in this study it was only 2 weeks. 
 
Reports have suggested that factors other than liver fibrosis, such as steatosis23, may influence 
LSM readings. To evaluate this question we performed multivariable analysis including all 
potentially relevant factors and notably the only factor that predicted LSM was the degree of 
liver fibrosis. Explicitly, neither the degree of steatosis or inflammation was associated with 
differences in LSM. This is likely because prior studies had not included other factors such as 
degree of fibrosis in their analyses, which when taken into account reveal that other histological 
elements do not influence LSM readings23. Also these studies only used the M probe which is 
likely to give an incorrect reading in many patients with NAFLD. Similarly, groups have 
suggested that LSM cut-offs differ according to probe choice20, 26, although in this study we 
did not find this to be the case.  
 
The threshold values will also be significantly impacted by the prevalence of the underlying 
condition. In Table 4 the effect of changing prevalence is demonstrated again allowing for 
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appropriate choice of cut-off values depending on the clinical setting. This modelling data 
demonstrates that as the prevalence of liver fibrosis (≥F2 or F4) decreases there is a 
commensurate reduction in PPV and increase in NPV. This is relevant as cut-offs generated in 
secondary care are often applied in primary care without taking into account the marked 
difference in prevalence. In this situation a negative test would be very reassuring although a 
positive test would have a low likelihood of capturing a true positive and raises the question of 
needing further confirmatory tests. 
 
Conventional cut-off criteria for grades of steatosis and fibrosis whilst useful, do not capture 
the importance to clinical decision making and its dependence on the relevant clinical setting. 
To better model this we explored two settings; one in which the presence of ≥F2 or F4 was 
being tested (Supplementary Appendix). In the former setting (≥F2) the assumption was made 
that a false positive was two, five or ten times worse than a false negative, with concomitant 
increases in the threshold. In contrast for F4 the opposite view was taken, namely that it was 
more important to not miss a diagnosis (Supplementary Table 114). This allows for healthcare 
organisations to make decision depending on how they value the ratio of false positive to false 
negatives. 
 
Our study has several strengths; it is a large prospective appropriately powered study, and 
captures real world clinical practice of clinicians evaluating patients with potential NAFLD. 
By incorporating the automatic probe recommendation tool we also ensured that the correct 
probe was used to generate LSM and CAP values. It defines a number of cut-offs which can 
be used according to the clinical setting and also provides modelling data on the impact of 
prevalence on performance. 
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A potential weakness of our study is that a number of biopsies were not interpretable as they 
did not show NAFLD but there again this is representative of real-world examination of this 
technology. In addition, we did not establish whether repeat VTCE examination would have 
generated consistent readings as demonstrated recently20. 
 
In summary, this study confirms the high applicability/low failure rate of VTCE in a cohort of 
patients with potential NAFLD, and demonstrate that LSM readings are not influenced by other 
histological components or choice of probe. Finally, our study provides a comprehensive range 
of cut-offs for LSM and CAP depending on the value a clinician places on false positive/false 
negatives as well as taking into account the prevalence of the degree of fibrosis. This will be 
critical for the roll-out of VTCE in a range of clinical settings. 
  
27 
 
Figure legends 
 
Figure 1. Study flow chart.  
Of 450 patients enrolled, 433 were eligible, 415 had the FibroScan examination performed and 
404 had a valid FibroScan examination. Eventually 383 had a valid controlled attenuation 
parameter (CAP) measurements and steatosis grade assessed on liver biopsy (LB) and 373 had 
a valid liver stiffness measurement (LSM) and fibrosis stage assessed on LB. 
 
Figure 2. Boxplot of (a) controlled attenuation parameter (CAP) versus steatosis grade, 
(b) liver stiffness measurement (LSM) versus fibrosis stage.  
(a) CAP values increase with increasing steatosis grade (Kruskal–Wallis test p < 10-16, Dunn's 
post hoc tests, p = 0.19 between CAP in S2 and CAP in S3, p < 10-3 otherwise); (b) LSM values 
increase significantly with increasing fibrosis stage (Kruskal-Wallis p < 10-16; Dunn's post hoc 
tests, p = 1 between LSM in F0 and LSM in F1, p < 0.05 otherwise).  
 
Figure 3. Boxplot of LSM versus fibrosis stage stratified by (a) probe type, (b) quartile of 
semi-quantitative steatosis percentage. 
The boxplot represent the LSM distribution for each fibrosis stage (a) according to the probe 
used. Patients were scanned either with the M or XL probe as proposed by the automatic probe 
recommendation tool. (b) stratified by steatosis amount: for each fibrosis stage, patients are 
stratified by steatosis quartile in the fibrosis stage.  
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Table legends 
 
Table 1. Patient characteristics 
 
Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for steatosis 
grade greater or equal than 1, greater or equal than 2 and equal to 3. 
 
Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis 
stage greater or equal than 2, greater or equal than 3 and equal to 4. 
 
Table 4. Impact of prevalence of F≥F2 and F=4 on positive predictive value (PPV) and 
negative predictive value (NPV) for cut-offs. 
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Table 1. Patient characteristics 
Characteristic N Distribution Range 
Centre 383 
Birmingham: 102 (27%) 
Newcastle: 51 (13%) 
London: 52 (14%) 
Nottingham: 40 (10%) 
Plymouth: 48 (13%) 
Cambridge: 60 (16%) 
Oxford: 30 (8%)  
─ 
Age (years) 383 54 [18] [19-77] 
BMI (kg.m-2) 383 33.8 [9.2],  [19.5-53.2] 
Female gender 383 171 (45%) ─ 
Diabetes mellitus 383 193 (50%) ─ 
Hypertension 383 207 (54%) ─ 
Hypercholesterolemia 383 199 (52%) ─ 
Platelets count (x109/L) 373 236 [84] [57-446] 
INR 361 1.08 [0.09] [0.81-2.54] 
AST (IU/L) 378 36 [25] [9-203] 
ALT (IU/L) 378 50 [40] [7-298] 
GGT (IU/L) 378 59 [88] [9-1718] 
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Alkaline phosphatase (IU/L) 377 82 [40] [4-738] 
Albumin (g/dL) 379 4.5 [0.4] [3.6-5.5] 
Bilirubin (mg/dL) 378 0.50 [0.35] [0.12-3.96] 
Fasting glucose (mg/dL) 376 106 [51] [50-312] 
Total cholesterol (mg/dL) 363 179 [64] [80-274] 
HDL cholesterol (mg/dL) 351 43 [17] [15-101] 
LDL cholesterol (mg/dL) 350 102 [51] [3-189] 
Triglyceride (mg/dL) 362 161 [92] [51-501] 
Ferritin (ng/mL) 378 134 [214] [7-4320] 
Urea (mg/dL) 378 29 [11] [12-84] 
Creatinine (mg/dL) 379 0.85 [0.22] [0.36-1.94] 
A2M (mg/dL) 376 205 [121] [91-523] 
Hyaluronic acid (ug/L) 379 40 [55] [19-1850] 
CRP (mg/dL) 378 0.31 [0.47] [0.02-7.53] 
CK18-M30 (IU/L) 369 415 [395] [74-1825] 
Time between FibroScan and 
liver biopsy (day) 
383 0 [7] [0-14] 
XL probe 383 255 (67%) ─ 
LSM (kPa), range 1.5-75 kPa 383 8.8 [7.8] [1.7-75.0] 
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CAP (dB/m), range 100-400 
dB/m 
380 336 [74] [100-400] 
Length of liver biopsy 
specimen (mm) 
383 23 [10] [5-60] 
Fibrosis stage 373 
F0: 62 (17%) 
F1: 86 (23%) 
F2: 85 (23%) 
F3: 106 (28%) 
F4: 34 (9%)  
─ 
Steatosis grade 383 
S0: 47 (12%) 
S1: 89 (23%) 
S2: 109 (28%) 
S3: 138 (36%) 
─ 
Ballooning grade 383 
B0: 106 (28%) 
B1: 147 (38%) 
B2: 130 (34%) 
─ 
Lobular inflammation grade 383 
I0: 90 (23%)  
I1: 235 (61%)  
I2: 51 (13%)  
I3: 7 (2%) 
─ 
NAS score 383 
0-2: 90 (23%) 
3-4: 122 (32%) 
─ 
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5-8: 171 (45%) 
Activity grade (according to 
SAF) 
383 
A0: 55 (14%)  
A1: 80 (21%)  
A2: 102 (27%)  
A3: 110 (29%) 
A4: 36 (9%) 
─ 
Portal inflammation present 382 172 (45%) ─ 
Pathologists diagnosis 383 
Normal liver: 17 (4%) 
NAFL: 91 (24%) 
NASH: 242 (63%) 
Other: 33 (9%) 
─ 
Distribution is expressed as median [interquartile range] or figure (percentage). 
A2M: alpha-2 macroglobulin, ALT: alanine transaminase, AST: aspartate aminotransferase, 
BMI: body mass index, CK18-M30: cytokeratin 18 neoepitope M30, CAP: controlled 
attenuation parameter, CRP: C-reactive protein, GGT: gamma-glutamyl transferase, HDL: 
high-density lipoprotein, INR: international normalized ratio, LDL: low-density lipoprotein, 
LSM: liver stiffness measurement, NAFL: non-alcoholic fatty liver, NAFLD: NAFL disease, 
NASH: non-alcoholic steato-hepatitis, NAS: NAFLD activity score. 
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Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for steatosis grade greater or equal than 1, greater or equal 
than 2 and equal to 3. 
 S≥S1 (≥5% steatosis) S≥S2 (≥34% steatosis) S=S3 (≥67% steatosis) 
AUROC (95%CI) 0.87 (0.82-0.92) 0.77 (0.71-0.82) 0.70 (0.64-0.75) 
Prevalence (N) 0.88 (N=303) 0.64 (N=244) 0.36 (N=137) 
Youden 
 Index 
Cut-off (dB/m) 302 331 337 
Se (95%CI) 
TP/(TP+FN) 
Sp (95%CI) 
TN/(TN+FP) 
0.80 (0.75-0.84) 
(266/333) 
0.83 (0.69-0.92) 
(39/47) 
0.70 (0.63-0.75) 
(170/244) 
0.76 (0.68-0.83) 
(104/136) 
0.72 (0.63-0.79) 
(98/137) 
0.63 (0.56-0.69) 
(152/243) 
PPV (95% CI)  
NPV (95% CI) 
0.97 (0.94-0.98) 
0.37 (0.31-0.59) 
0.84 (0.78-0.88) 
0.58 (0.52-0.68) 
0.52 (0.45-0.62) 
0.80 (0.73-0.84) 
LR+ (95% CI) 4.69 (2.49-8.84) 2.96 (2.16-4.05) 1.91 (1.57-2.32)   
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LR- (95% CI) 0.24 (0.19-0.31) 0.40 (0.32-0.49) 0.46 (0.34-0.60) 
Se=0.90 
Cut-off (dB/m) 274 290 302 
Se (95%CI) 
TP/(TP+FN) 
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.90 (0.87-0.93) 
(301/333) 
Sp = 0.60 (0.44-0.74) 
(28/47) 
Se = 0.90 (0.86-0.94) 
(220/244) 
Sp = 0.44 (0.36-0.53) 
(60/136) 
Se = 0.90 (0.83-0.94) 
(123/137) 
Sp = 0.38 (0.32-0.44) 
(92/243) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.94 (0.90-0.96) 
NPV = 0.47 (0.38-0.62) 
PPV = 0.74 (0.67-0.82) 
NPV = 0.71 (0.62-0.78) 
PPV = 0.45 (0.38-0.61) 
NPV = 0.87 (0.79-0.90) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 2.24 (1.58-3.17) 
LR- = 0.16 (0.11-0.24) 
LR+ = 1.61 (1.38-1.88) 
LR- = 0.22 (0.15-0.34) 
LR+ = 1.44 (1.29-1.62) 
LR- = 0.27 (0.16-0.45) 
Sp=0.90 
Cut-off (dB/m) 325 370 398 
Se (95%CI) 
TP/(TP+FN) 
Se = 0.66 (0.61-0.71]) 
(220/333) 
Se = 0.34 (0.28-0.40) 
(83/244) 
Se = 0.14 (0.09-0.21) 
(19/137) 
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Sp (95%CI) 
TN/(TN+FP) 
Sp = 0.90 (0.77-0.96) 
(42/47) 
Sp = 0.90 (0.83-0.94) 
(122/136) 
Sp = 0.90 (0.86-0.94) 
(219/243) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.98 (0.95-0.98) 
NPV = 0.27 (0.23-0.55) 
PPV = 0.86 (0.77-0.89) 
NPV = 0.43 (0.36-0.59) 
PPV = 0.44 (0.34-0.56) 
NPV = 0.65 (0.52-0.75) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 6.21 (2.70-14.27 
LR- = 0.38 (0.32-0.45) 
LR+ = 3.30 (1.95-5.59) 
LR- = 0.74 (0.66-0.82) 
LR+ = 1.40 (0.80-2.47) 
LR- = 0.96 (0.88-1.03) 
 
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-: 
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, S: steatosis, Se: sensitivity, 
Sp: specificity, TN: true negative, TP: true positive. 
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Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis stage greater or equal than 2, greater or equal 
than 3 and equal to 4. 
 F≥F2 F≥F3 F=F4 
AUROC (95%CI) HIS 0.80 (0.75-0.84) 0.89 (0.84-0.93) 
Prevalence (N) 0.60 (N=225) 0.38 (N=140) 0.09 (N=34) 
Youden 
 Index 
Cut-off (kPa) 8.2 9.7 13.6 
Se (95%CI) 
TP/(TP+FN)  
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.71 (0.64-0.77) 
(159/225) 
Sp = 0.70 (0.62-0.77) 
(103/148) 
Se = 0.71 (0.62-0.78) 
(99/140) 
Sp = 0.75 (0.69-0.80) 
(174/233) 
Se = 0.85 (0.69-0.95) 
(29/34) 
Sp = 0.79 (0.74-0.83) 
(267/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.78 (0.71-0.83) 
NPV = 0.61 (0.54-0.69) 
PPV = 0.63 (0.55-0.71) 
NPV = 0.81 (0.74-0.85) 
PPV = 0.29 (0.24-0.57) 
NPV = 0.98 (0.95-0.99) 
LR+ (95% CI) LR+ = 2.32 (1.80-3.01) LR+ = 2.79 (2.19-3.57) LR+ = 4.02 (3.13-5.15) 
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LR- (95% CI) LR- = 0.42 (0.34-0.53) LR- = 0.39 (0.30-0.51) LR- = 0.19 (0.08-0.42) 
Se=0.90 
Cut-off (kPa) 6.1 7.1 10.9 
Se (95%CI) 
TP/(TP+FN)  
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.90 (0.86-0.94) 
(203/225) 
Sp = 0.38 (0.30-0.46) 
(56/148) 
Se = 0.90 (0.84-0.94) 
(126/140) 
Sp = 0.50 (0.43-0.56) 
(116/233) 
Se = 0.91 (0.76-0.98) 
(31/34) 
Sp = 0.70 (0.64-0.74) 
(236/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.69 (0.61-0.78) 
NPV = 0.72 (0.62-0.78) 
PPV = 0.52 (0.45-0.67) 
NPV = 0.89 (0.83-0.92) 
PPV = 0.23 (0.19-0.61) 
NPV = 0.99 (0.96-0.99) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 1.45 (1.27-1.66) 
LR- = 0.26 (0.17-0.40) 
LR+ = 1.79 (1.56-2.06) 
LR- = 0.20 (0.12-0.34) 
LR+ = 3.00 (2.48-3.64) 
LR- = 0.13 (0.04-0.37) 
Sp=0.90 
Cut-off (kPa) 12.1 14.1 20.9 
Se (95%CI) 
TP/(TP+FN) 
Se = 0.44 (0.38-0.51) 
(100/225) 
Se = 0.48 (0.39-0.56) 
(67/140) 
Se = 0.59 (0.41-0.75) 
(20/34) 
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Sp (95%CI) 
TN/(TN+FP) 
Sp = 0.91 (0.85-0.95) 
(134/148) 
Sp = 0.90 (0.86-0.94) 
(210/233) 
Sp = 0.90 (0.86-0.93) 
(305/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.88 (0.80-0.90) 
NPV = 0.52 (0.45-0.67) 
PPV = 0.74 (0.65-0.80) 
NPV = 0.74 (0.67-0.82) 
PPV = 0.37 (0.29-0.56) 
NPV = 0.96 (0.91-0.97) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 4.70 (2.79-7.90) 
LR- = 0.61 (0.54-0.70) 
LR+ = 4.85 (3.17-7.41) 
LR- = 0.58 (0.49-0.68) 
LR+ = 5.87 (3.83-8.97) 
LR- = 0.46 (0.31-0.69) 
 
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-: 
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp: 
specificity, TN: true negative, TP: true positive. 
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Table 4. Impact of prevalence of F≥F2, F≥F3 and F=4 on positive predictive value (PPV) and negative predictive value (NPV) together 
with their (95% confidence interval) of LSM for the cutoff for Se=0.90, for the Youden index cutoff and for the cutoff for Sp=0.90. 
 Prevalence Justification Cutoff for Se=0.90 Youden index cutoff Cutoff for Se=0.90 
Diagnostic 
of 
F≥F2 
- - Cutoff = 6.1 kPa Cutoff = 8.2 kPa Cutoff = 12.1 kPa 
60% 
Actual prevalence in 
our population 
PPV=69% (66%-71%) 
NPV=72% (62%-80%) 
PPV=78% (73%-82%) 
NPV=61% (56%-67%) 
PPV=88% (81%-92%) 
NPV=52% (49%-55%) 
40% 
Estimated prevalence in 
diabetic clinic 42 
PPV=49% (46%-53%) 
NPV=85% (79%-90%) 
PPV=61% (54%-67%) 
NPV=78% (74%-82%) 
PPV=76% (65%-84%) 
NPV=71% (68%-74%) 
7% 
Estimated prevalence in 
general population 40 
PPV=10% (9%-11%) 
NPV=98% (97%-99%) 
PPV=15% (12%-18%) 
NPV=97% (96%-98%) 
PPV=26% (17%-37%) 
NPV=96% (95%-96%) 
Diagnostic 
of 
F≥F3 
- - Cutoff = 7.1 kPa Cutoff = 9.7 kPa Cutoff = 14.1 kPa 
38% 
Actual prevalence in 
our population 
PPV = 52% (45%-67%) 
NPV = 89% (83%-92%) 
PPV = 63% (55%-71%) 
NPV = 81% (74%-85%) 
PPV = 74% (65%-80%) 
NPV = 74% (67%-82%) 
18% 
Estimated prevalence in 
diabetic clinic 42 
PPV=28% (24%-32%) 
NPV=96% (92%-98%) 
PPV=38% (30%-46%) 
NPV=92% (89%-94%) 
PPV=52% (37%-66%) 
NPV=89% (87%-91%) 
2% 
Estimated prevalence in 
general population 41 
PPV=4% (3%-4%) 
NPV=99.6% (99.2%-99.8%) 
PPV=5% (4%-7%) 
NPV=99.2% (98.9%-99.4%) 
PPV=9% (5%-15%) 
NPV=98.8% (98.6%-99.1%) 
Diagnostic - - Cutoff = 10.9 kPa Cutoff = 13.6 kPa Cutoff = 20.9 kPa 
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of 
F=F4 
9% 
Actual prevalence in 
our population 
PPV=23% (20%-26%) 
NPV=98.7% (96.5%-99.6%) 
PPV=28% (24%-34%) 
NPV=98.2% (96.0%-99.2) 
PPV=37% (27%-47%) 
NPV=95.7% (93.7%-97.1%) 
3% 
Estimated prevalence in 
population at risk of 
liver disease 41 
PPV=8% (7%-10%) 
NPV=99.6% (98.9%-99.9%) 
PPV=11% (9%-14%) 
NPV=99.4% (98.7%-99.8%) 
PPV=15% (11%-22%) 
NPV=98.6% (97.9%-99.1%) 
1% 
Estimated prevalence in 
general population 41 
PPV=3% (2%-4%) 
NPV=99.9% (99.6%-100%) 
PPV=4% (3%-5%) 
NPV=99.8% (99.6%-99.9%) 
PPV=6% (4%-8%) 
NPV=99.5% (99.3%-99.7%) 
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